Antibody–Prodrug Conjugates with KSP Inhibitors and Legumain‐Mediated Metabolite Formation
出版年份 2019 全文链接
标题
Antibody–Prodrug Conjugates with KSP Inhibitors and Legumain‐Mediated Metabolite Formation
作者
关键词
-
出版物
CHEMISTRY-A EUROPEAN JOURNAL
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2019-03-14
DOI
10.1002/chem.201900441
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Antibody-drug conjugates with pyrrole-based KSP inhibitors as novel payload class
- (2018) Hans-Georg Lerchen et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- MORAb-202, an antibody drug conjugate utilizing humanized anti-human FRa farletuzumab and the microtubule-targeting agent eribulin, has potent anti-tumor activity
- (2018) Xin Cheng et al. MOLECULAR CANCER THERAPEUTICS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Structure and function of legumain in health and disease
- (2016) Elfriede Dall et al. BIOCHIMIE
- Abstract 1210: Preclinical pharmacology and repeated dose toxicity of the novel agonistic TWEAK receptor binding antibody BAY-356
- (2016) Sandra Berndt et al. CANCER RESEARCH
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- High expression of the cysteine proteinase legumain in colorectal cancer – Implications for therapeutic targeting
- (2015) Mads H. Haugen et al. EUROPEAN JOURNAL OF CANCER
- Clinicopathologic significance of legumain overexpression in cancer: a systematic review and meta-analysis
- (2015) Ye Zhen et al. Scientific Reports
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- B7-H3-mediated tumor immunology: Friend or foe?
- (2013) Ling Wang et al. INTERNATIONAL JOURNAL OF CANCER
- Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity
- (2012) D. Loo et al. CLINICAL CANCER RESEARCH
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Brentuximab Vedotin (SGN-35)
- (2011) J. Katz et al. CLINICAL CANCER RESEARCH
- Targeting Cell Surface Alpha(v)beta(3) Integrin Increases Therapeutic Efficacies of a Legumain Protease-Activated Auristatin Prodrug
- (2011) Yuan Liu et al. MOLECULAR PHARMACEUTICS
- Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma
- (2010) Jing Sun et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- The Legumain Protease-Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without Toxicity
- (2010) Krishna Mohan Bajjuri et al. ChemMedChem
- A Novel Antitumor Prodrug Platform Designed to Be Cleaved by the Endoprotease Legumain
- (2009) Liron Stern et al. BIOCONJUGATE CHEMISTRY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started